Elena Cabezas

Elena Cabezas

Auto-generated profile, based on publicly available information

Elena Cabezas

Ramón y Cajal University Hospital, Ramón y Cajal Health Research Institute (IRYCIS), Department of Gynecologic Oncology, Madrid, Spain

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CMCristina Martínez-Payo
Cristina Martínez-Payo
ECElena Cabezas
Elena Cabezas
YNYolanda Nieto
Yolanda Nieto
MAMiguel Ruiz de Azúa
Miguel Ruiz de Azúa
FGFátima García-Benasach
Fátima García-Benasach
EIEnrique Iglesias
Enrique Iglesias
Introduction. The value of a single umbilical artery (SUA) in first trimester ultrasound is not well established. The aim of our study was to determinate the relevance of diagnosis of single umbilical artery in first trimester ultrasound as an early marker suggesting the presence of malformations or associated chromosomopathies.Material and Methods. Retrospective study of clinical cases of SUA diagnosed at the University Hospital Puerta de Hierro in Madrid (Spain) during the first trimester ultrasound between September 2008 and September 2012.Results. Prevalence of SUA was 1.1% in single pregnancies and 3.3% in twin pregnancies. Sensitivity, specificity, false positive rate, and false negative rate for the finding in the first trimester were 84.2, 99.8, 0.2, and 15.7%, respectively. 17.6% of cases had associated malformations. With an ultrasound in the 16th week most of the cases with significant fetal malformation were diagnosed.Discussion. SUA is a useful marker in the first trimester for fetal malformation pathology, as it will allow detecting a large number of cases with malformations before 20 weeks of gestation.

1 June 2016 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
ELElena Cabezas López
Elena Cabezas López
CMCristina Martínez-Payo
Cristina Martínez-Payo
VCVirginia Engels Calvo
Virginia Engels Calvo
LLLuis San Frutos Llorente
Luis San Frutos Llorente
TMTirso Pérez Medina
Tirso Pérez Medina

8 September 2014 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
ECE. Cabezas
E. Cabezas
CMC. Martínez-Payo
C. Martínez-Payo
YCY. Chiverto
Y. Chiverto
YJY. Nieto Jimenez
Y. Nieto Jimenez
MAM. Ruiz de Azúa
M. Ruiz de Azúa
EIE. Iglesias
E. Iglesias

7 February 2026 in International Journal of Gynecological Cancer
Verified
Journal Article
Open access
EMEsther Moreno-Moreno
Esther Moreno-Moreno
TCTamara Caniego-Casas
Tamara Caniego-Casas
IRIgnacio Ruz-Caracuel
Ignacio Ruz-Caracuel
ICIrene Carretero-Barrio
Irene Carretero-Barrio
ECElena Cabezas-López
Elena Cabezas-López
BPBelén Pérez-Mies
Belén Pérez-Mies
This study aimed to assess the frequency of MDM4 amplification in endometrial carcinomas and its association with clinicopathological features, particularly relapse risk in early-stage low-grade endometrioid endometrial carcinoma. We conducted a case-control study including 110 stage I to II low-grade endometrioid endometrial carcinomas (39 relapsing and 71 non-relapsing tumors) and an additional cohort of 82 high-grade endometrial carcinomas. An independent retrospective cohort of 194 early-stage low-grade endometrioid endometrial carcinomas was used to validate the results. MDM4 amplification was analyzed by fluorescent in situ hybridization. Gene expression of MDM4 and GADD45A was measured by quantitative real-time polymerase chain reaction. Immunohistochemistry assessed hormone receptor status, p53, and mismatch repair proteins. POLE and CTNNB1 mutations were evaluated by Sanger sequencing. MDM4 amplification was detected in 31 of 186 tumors (16.7%): 14 of 104 low-grade endometrioid endometrial carcinomas (13.5%) and 17 of 82 high-grade endometrial carcinomas (20.7%). Among low-grade endometrioid endometrial carcinomas, amplification was significantly more frequent in relapsing tumors (11/38, 28.9%) than in non-relapsing ones (3/66, 4.5%) (p <.01). Concordant MDM4 amplification status was observed between biopsies and hysterectomy samples. In some relapsing cases, amplification emerged during disease progression. Multi-variable Cox regression identified MDM4 amplification as an independent predictor of relapse, alongside lymphovascular space invasion, tumor necrosis, and myometrial invasion. In the independent cohort, MDM4 amplification was associated with progression-free survival. Our study suggested that MDM4 amplification is a potential predictor of the risk of recurrence in early-stage low-grade endometrioid endometrial carcinoma that can be easily evaluated in endometrial samples.

1 September 2015
Verified
Conference Paper
Closed access
MPM Teresa Pérez-Warnisher
M Teresa Pérez-Warnisher
SAS. Vicente Antunes
S. Vicente Antunes
ECE. Cabezas
E. Cabezas
GMGuillermo Gallardo Madueño
Guillermo Gallardo Madueño
AAA. Alcazar
A. Alcazar
LSL. Seijo
L. Seijo
Introduction: Lung cancer screening using low dose CT (LDCT) reduces mortality in a population at risk. The number of subjects needed to screen may pose a significant challenge to a national health service. We sought to investigate the feasibility a lung cancer screening program using LDCT in a restricted population of very high risk individuals. Patients and Methods: Prospective data on the first 94 subjects enrolled in the LDCT screening program at our hospital were included in this pilot study. Among patients meeting NLST criteria, only those with emphysema, COPD, and/or nodules will undergo annual screening. Screening was performed according to the consensus International Early Lung Cancer Action Program (IELCAP) protocol. Results: Of the 94 subjects included in the program thus far, 5 (5.3%) failed to undergo baseline testing. Mean age of those undergoing baseline LDCT was 63.17 SD(6.5) with a median tobacco exposure of 50 (IQR: 40-80) pack-years. 60% were current smokers, 58 patients had COPD and 75 had emphysema (84%). Mean FEV1 was 2.06 L (DS 0.63) which was 76% of predicted and 39 subjects (43.8%) had a diffusing capacity of carbon monoxide below 80% of predicted. One patient required bronchoscopy for cryptogenic organizing pneumonia (COP). Ten patients (11%) had nodules ≥ 6mm. Four of them had a follow up LDTC at 3 months. The remaining 6 patients are awaiting follow up LDCT. Conclusions: Lung cancer screening is feasible in patients with COPD and/or emphysema meeting NLST criteria. Despite concerns regarding excess positive screening findings in this population, nodules 6 mm or greater are relatively rare in this population of very high risk individuals.

1 October 2016 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
ECE. Cabezas
E. Cabezas
VEV. Engels
V. Engels
ARA. Royuela
A. Royuela
CMC. Martínez-Payo
C. Martínez-Payo
LFL. San Frutos
L. San Frutos
TPT. Pérez-Medina
T. Pérez-Medina